Status of anaplastic lymphoma kinase (ALK) in malignant mesothelioma

Anticancer Research

Volumn 34, Issue 5, 2014, Pages 2589-2592

  Varesano, Serena ^a   Leo, Claudio ^a   Boccardo, Simona ^a   Salvi, Sandra ^a   Truini, Mauro ^a   Ferro, Paola ^b   Fedeli, Franco ^b   Canessa, Pier Aldo ^c   Dessanti, Paolo ^b   Pistillo, Maria Pia ^d   Roncella, Silvio ^a  

^a PO sant'Andrea ASL5   (Italy)

^b Division of Histopathology and Cytopathology   (Italy)

^c Division of Pneumology   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

Anaplastic lymphoma kinase; Crizotinib; Fluorescent in situ hybridization; Immunohistochemistry; Malignant mesothelioma; Targeted therapy

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; PROTEIN TYROSINE KINASE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CHILD; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; PROTEIN EXPRESSION; AGED; BIOSYNTHESIS; ENZYMOLOGY; GENETICS; LUNG TUMOR; MESOTHELIOMA; MIDDLE AGED; MUTATION; PRESCHOOL CHILD; TARGETED THERAPY; VERY ELDERLY; YOUNG ADULT;

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; FLUORESCENT IN SITU HYBRIDIZATION; IMMUNOHISTOCHEMISTRY; MALIGNANT MESOTHELIOMA; TARGETED THERAPY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; MUTATION; RECEPTOR PROTEIN-TYROSINE KINASES; YOUNG ADULT;

EID: 84903139993     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Peto J, Decarli A, La Vecchia C, Levi F and Negri E: The European mesothelioma epidemic. Br J Cancer 79: 666-672, 1999.
2. INAIL. The National Register of Mesotheliomas (ReNaM). Fourth assessment report, 2012. http://www.ispesl.it/renam/Index.asp. Access 19 December 2013.
3. Canessa PA, Franceschini MC, Ferro P, Battolla E, Dessanti P, Manta C, Sivori M, Pezzi R, Fontana V, Fedeli F, Pistillo MP, Roncella S: Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology. Cancer Invest 31: 43-50, 2013.
4. Ismail-Khan R, Robinson LA, Williams CC Jr, Garrett CR, Bepler G, Simon GR: Malignant pleural mesothelioma: a Comprehensive Review. Cancer Control 13: 255-263, 2006.
5. Vincent MD, Kuruvilla MS, Leighl NB and Kamel-Reid S: Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS. Curr Oncol 19: 33-44, 2012.
6. FDA. Highlights of prescribing information. U.S. Food and Drug Administration. 2011. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/202570s000lbl.pdf. Access 11 December 2013.
7. Mano H: Non-solid oncogenes in solid tumors EML4-ALK fusion genes in lung cancer. Cancer Sci 99: 2349-2355, 2008.
8. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ: Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. N Engl J Med 363: 1693-1703, 2010.
9. Schonherr C, Hallberg B, Palmer R: Anaplastic lymphoma kinase in human cancer. Crit Rev Oncog 17: 123-143, 2012.
10. Murakami Y, Mitsudomi T, Yatabe Y: A screening method for the ALK fusion gene in NSCLC. Front Oncol 2: 1-9, 2012.
11. Méndez M, Custodio A, Provencio M: New molecular targeted therapies for advanced NSCLC. J Thorac Dis 3: 30-56, 2011.
12. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H: Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature 448: 561-562, 2007.
13. Paik JH, Choe G, Kim H, Choe JY, Lee HJ, Lee CT, Lee JS, Jheon S, Chung JH: Screening of Anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer-correlation with fluorescence in situ hybridization. J Thorac Oncol 6: 466-472, 2011.
14. Pillai RN, Ramalingam S: The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation. Curr Oncol Rep 14: 105-110, 2012.